AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2499464
Drug: Adenosine (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (bolus doses of 5.3 to 15.9 mg)
Trial: 2499464
Drug: Theophylline (58.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (58.3 +/- 3.3 mumol l‐1 plasma)
Trial: 2499464
Drug: Dipyridamole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (10 mg)
Trial: 842760
Drug: Vitamin and
RxNorm normalized name: Vitamin and Mineral Supplement
DrugBank: alpha-Tocopherol acetate (DB14003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin and mineral supplement with one‐third of the calories
Trial: 30926369
Drug: M1095 (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M1095 (240 mg)
Trial: 30926369
Drug: M1095 (30,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M1095 (30, 60, 120, or 240 mg)
Trial: 27845200
Drug: High-dose KME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose KME (2g/d)
Trial: 27845200
Drug: KME groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KME groups (low-dose and high-dose)
Trial: 26870788
Drug: Linezolid 300
RxNorm normalized name: linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid 300 mg
Trial: 26870788
Drug: Linezolid (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (both doses)
Trial: 19262457
Drug: Metilprednisolone (steroids)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metilprednisolone (steroids)
Trial: 15272899
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 0.75 mg/kg on alternate days, plus vitamin D 600-1200 units/day and a calcium-enriched diet
Trial: 9242341
Drug: Interleukin-1 receptor
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Interleukin-1 receptor antagonist (IL-1ra) 100 mg bolus followed by 2 mg/kg per hour intravenously for 72 hours (n = 20)
Trial: 8494702
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy including alkylating agents (n = 14)
Trial: 15983288
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (0.8 mg/d)
Trial: 10372975
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (850 mmol L(‐1))
Trial: 10372975
Drug: Time control
RxNorm normalized name: BENZOYL PEROXIDE 50 mg in 1 mL TOPICAL LOTION [Nighttime Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time control (no saline infusion)
Trial: 4539414
Drug: Cholera vaccine
RxNorm normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera vaccine (1 dose)
Trial: 4539414
Drug: Cholera vaccine
RxNorm normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera vaccine (2 doses)
Trial: 4539414
Drug: Cholera vaccine
RxNorm normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera vaccine (3 doses)
Trial: 4539414
Drug: Cholera vaccine
RxNorm normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera vaccine (4 doses)
Trial: 4539414
Drug: Cholera vaccine
RxNorm normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera vaccine (1 dose annually for 3 years)
Trial: 4539414
Drug: Cholera vaccine
RxNorm normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera vaccine (2 doses in the first year followed by annual reimmunizations)
Trial: 4539414
Drug: Cholera vaccine
RxNorm normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera vaccine (after 4 doses)
Trial: 24377216
Drug: Acupuncture group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture group (shu‐stream point acupuncture combined with fire needle therapy)
Trial: 24377216
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (votalin emulgel)
Trial: 11738912
Drug: Ciprofloxacin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (2 oral 500 mg doses at 12-hour intervals)
Trial: 11738912
Drug: Levofloxacin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (single oral 500 mg dose)
Trial: 11738912
Drug: Moxifloxacin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (single oral 400 mg dose)
Trial: 8996152
Drug: Mitomycin as
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin as an adjunct to radiation therapy
Trial: 8214177
Drug: Social support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social support group therapy (8 sessions)
Trial: 3677279
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate (0.4 ml.kg‐1)
Trial: 28947724
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose rivaroxaban
Trial: 27716128
Drug: Tailored Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored Treatment (TT)
Trial: 27716128
Drug: Non-Tailored Treatment
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Tailored Treatment (NTT)
Trial: 24534128
Drug: Eptifibatide plus
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide plus rt-PA (0.6 mg/kg rt-PA, 135 mcg/kg bolus, 0.75 mcg/kg/min two-hour infusion)
Trial: 24534128
Drug: rt-PA alone
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rt-PA alone (0.9 mg/kg)
Trial: 20613484
Drug: Epidural bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine (5, 10, 15, 20, 30, or 40 mg)
Trial: 20613484
Drug: Epidural ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ropivacaine (7, 15, 20, 30, 45, or 60 mg)
Trial: 18756037
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (154 mmol/L intravenous infusion, bolus of 3 ml.kg(‐1).h(‐1) for 1 h before contrast, followed by infusion of 1 ml.kg(‐1).h(‐1) for 6 h during and after the procedure)
Trial: 18756037
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride (154 mmol/L intravenous infusion, bolus of 3 ml.kg(‐1).h(‐1) for 1 h before contrast, followed by infusion of 1 ml.kg(‐1).h(‐1) for 6 h during and after the procedure)
Trial: 16738029
Drug: High ranking
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High ranking competitors (e.g., #2 vs. #3)
Trial: 16738029
Drug: Low ranking
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low ranking competitors (e.g., #202 vs. #203)
Trial: 16738029
Drug: Proximity to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proximity to meaningful standards (e.g., bottom of a ranking scale or qualitative threshold)
Trial: 11731729
Drug: labetalol 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol 0.2 mg/kg
Trial: 11731729
Drug: urapidil 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urapidil 25 mg
Trial: 7864425
Drug: no drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no drug
Trial: 2956872
Drug: Enoximone (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (150 mg, 3 times daily)
Trial: 2956872
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg, 3 times daily)
Trial: 2956872
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional therapy with diuretics)
Trial: 20149361
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist ganirelix
Trial: 31790144
Drug: Ketoconazole (steroidogenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (steroidogenic inhibitor)
Trial: 31790144
Drug: High-dose ganirelix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ganirelix and repeated LH infusions
Trial: 19057210
Drug: PDE-5 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PDE-5 inhibitors (sildenafil, vardenafil, tadalafil)
Trial: 9663723
Drug: OCT (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCT (omeprazole 20 mg q.d.s. + clarithromycin 250 mg b.d. + tinidazole 500 mg b.d.)
Trial: 9663723
Drug: CT (clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT (clarithromycin 250 mg b.d. + tinidazole 500 mg b.d.)
Trial: 9663723
Drug: OC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC (omeprazole 20 mg o.d. + clarithromycin 250 mg b.d.)
Trial: 9663723
Drug: C (clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C (clarithromycin 250 mg b.d.)
Trial: 9663723
Drug: OCT (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCT (in patients with pre-treatment metronidazole resistance)
Trial: 9663723
Drug: CT (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT (in patients with pre-treatment metronidazole resistance)
Trial: 9663723
Drug: C (post-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C (post-treatment resistance to clarithromycin)
Trial: 9663723
Drug: OC (post-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC (post-treatment resistance to clarithromycin)
Trial: 9663723
Drug: CT (post-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT (post-treatment resistance to both antibiotics)
Trial: 9663723
Drug: OCT (post-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCT (post-treatment resistance to both antibiotics)
Trial: 7933844
Drug: Constant infusion
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant infusion method
Trial: 11429362
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection technique
Trial: 31339232
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker
Trial: 27032074
Drug: All antihypertensive
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All antihypertensive medications
Trial: 23085706
Drug: Ultrasonography-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonography-guided injection
Trial: 18672254
Drug: Second IVIG
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second IVIG infusion (2 g/kg)
Trial: 16164708
Drug: Alefacept plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept plus UVB treatment (6-week and 12-week)
Trial: 16164708
Drug: Alefacept monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept monotherapy
Trial: 16164708
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (alefacept/UVB)
Trial: 12858653
Drug: Memantine 10
RxNorm normalized name: Memantine 10mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 10 mg twice daily for up to 28 weeks
Trial: 12858653
Drug: Memantine 10
RxNorm normalized name: Memantine 10mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 10 mg twice daily
Trial: 10371538
Drug: Topiramate (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (titrated to approximately 6 mg/kg/d)
Trial: 8898424
Drug: Recombinant interferon-alpha
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recombinant interferon-alpha 2a therapy for 26 weeks
Trial: 6295596
Drug: VP-16 (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VP-16 (180 mg/m2 on 3 consecutive days at 2 weekly intervals)
Trial: 22394471
Drug: Org 25935
RxNorm normalized name: ORG-25935
DrugBank: ORG-25935 (DB12220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 25935 (4 mg)
Trial: 20079620
Drug: Injecting drugs
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injecting drugs (general)
Trial: 16277632
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg rapid-release nicotine gum (RRNG)
Trial: 16277632
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine polacrilex gum (NPG)
Trial: 12804864
Drug: Ventrogluteal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventrogluteal injection of DTPw vaccine
Trial: 12804864
Drug: Ventrogluteal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventrogluteal injection of DTPa vaccine
Trial: 12804864
Drug: Ventrogluteal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventrogluteal injection of HibTITER vaccine
Trial: 12804864
Drug: Ventrogluteal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ventrogluteal injection
Trial: 12804864
Drug: Anterolateral thigh
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anterolateral thigh injection
Trial: 10605191
Drug: Triple combinations
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combinations including two nucleoside analogues and a potent protease inhibitor
Trial: 10605191
Drug: Protease inhibitors
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protease inhibitors and triple therapy
Trial: 8947337
Drug: Nasal allergen
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal allergen challenges after 4 years' immunotherapy
Trial: 6755307
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy + calcitonin
Trial: 6755307
Drug: Basic therapy
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic therapy + calcifediol
Trial: 29069568
Drug: Medical-therapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical-therapy group (n=59)
Trial: 21971755
Drug: Electrostimulation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrostimulation treatment protocol (30 sessions starting four days post-operation)
Trial: 10853696
Drug: Acute submaximal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute submaximal exercise with NO inhalation (mask)
Trial: 10853696
Drug: Acute submaximal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute submaximal exercise without NO inhalation (no mask)
Trial: 1325076
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin CY 216 (Fraxiparine) in a fixed dose
Trial: 1325076
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) in doses adjusted according to the activated partial thromboplastin time
Trial: 6465619
Drug: Pentoxifylline (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (1200 mg/day, Trental 400 tds.)
Trial: 6465619
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid and dipyridamole (1050 mg + 150 mg/day)
Trial: 29329305
Drug: TDF monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF monotherapy (n = 111)
Trial: 29329305
Drug: LAM+ADV combination
RxNorm normalized name: Viril Lam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAM+ADV combination therapy (n = 58)
Trial: 29329305
Drug: TDF monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF monotherapy (n = 111) with cirrhosis
Trial: 26823540
Drug: Monovalent rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent rotavirus vaccine (2 doses)
Trial: 26823540
Drug: Mixed vaccine
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed vaccine schedules (3 doses)
Trial: 26823540
Drug: Single vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vaccine reference groups (2 doses)
Trial: 22285609
Drug: multicomponent cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multicomponent cognitive‐behavioral therapy (CBT)
Trial: 22285609
Drug: multicomponent cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multicomponent cognitive‐behavioral therapy (CBT) with hypnosis
Trial: 22285609
Drug: standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard care (pharmacological treatment)
Trial: 17202433
Drug: Individualized dietary
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dietary modification + recombinant human growth hormone (GH) (0.1 mg/kg daily x 21 days, then 3 times/week)
Trial: 9791525
Drug: Intensified education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified education through a booklet about amblyopia and its treatment.
Trial: 7702027
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g fish-oil concentrate/d (approximately 3.4 g eicosapentaenoic and docosahexaenoic acids/d)
Trial: 7702027
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g fish-oil concentrate/d
Trial: 27530310
Drug: IVIG 1
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 1 g/kg/day for two consecutive days
Trial: 27530310
Drug: PLEX 1-L
RxNorm normalized name: Kleer Plex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLEX 1-L plasma exchange five times with 5% albumin replacement fluid, every other day, 10-30 days before the procedure
Trial: 16205904
Drug: Pregabalin fixed
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin fixed dose treatment
Trial: 16205904
Drug: Pregabalin flexible
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin flexible dose treatment
Trial: 15456623
Drug: Immunotherapy administered
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy administered in the initiation phase according to a cluster schedule of eight doses injected on four visits.
Trial: 15456623
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no immunotherapy).
Trial: 9237962
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of 2.1 mg d‐alpha‐tocopheryl acetate and 0.06 microg ergocalciferol per gram of olestra
Trial: 9237962
Drug: Olestra (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olestra (all doses)
Trial: 8233263
Drug: Ear, hand,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ear, hand, and foot reflexology treatment
Trial: 3317354
Drug: Recombinant yeast‐derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant yeast‐derived hepatitis B vaccine (3 doses of 40 micrograms) administered at 0, 1, 2 months
Trial: 3317354
Drug: Recombinant yeast‐derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant yeast‐derived hepatitis B vaccine (3 doses of 40 micrograms) administered at 0, 1, 6 months
Trial: 27225988
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy only (no stenting)
Trial: 23996068
Drug: BPTB reconstruction
RxNorm normalized name: CONSTRICTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPTB reconstruction with synthetic degradable augmentation device
Trial: 23996068
Drug: BPTB reconstruction
RxNorm normalized name: CONSTRICTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPTB reconstruction without augmentation